Postmarketing Studies Are Becoming the Norm in the U.S., Europe, and Japan, According to Tufts Center for the Study of Drug Development
10 juil. 2008 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - July 10, 2008) - Post-approval study commitments, in which drug
developers, as a condition of regulatory approval, agree to conduct
research on newly marketed prescription...
Effective Drug Development Metrics Link Operations With Strategy, According to Tufts Center for the Study of Drug Development
10 juin 2008 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - June 10, 2008) - Research-based drug companies looking to
streamline the development of new medicinal products should adopt metrics
that link their R&D activities with...
Medicare Prescription Drug Plans Not Fully Compliant With Federal Regulations, According to Tufts Center for the Study of Drug Development
06 mai 2008 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - May 6, 2008) - A new study by the Tufts Center for the Study of
Drug Development has found that Medicare prescription drug plans that came
into being following the landmark...
Effective Drug Development Outsourcing Requires a Plan, According to Tufts Center for the Study of Drug Development
02 avr. 2008 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - April 2, 2008) - While the trend to outsource key elements of
drug development to service providers could slow down due in part to rising
operating costs worldwide, drug...
Number of Monoclonal Antibody Products in Development Nearly Tripled in Last Decade, According to Tufts Center for the Study of Drug Development
11 mars 2008 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - March 11, 2008) - The number of monoclonal antibody products --
known as mAbs -- entering clinical study nearly tripled in the last decade
and now require 7.6 years on...
Pharmaceutical and Biopharmaceutical Companies Need to Reassess the Way They Operate, According to Tufts Center for the Study of Drug Development
05 févr. 2008 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - February 5, 2008) - How drug developers organize their companies
affects operational and financial performance, according to new research
findings presented to a panel of...
Tufts Center for the Study of Drug Development to Launch R&D Senior Management Roundtable Series Feb. 28
28 janv. 2008 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - January 28, 2008) - The Tufts
Center for the Study of Drug Development today announced that it is
expanding its R&D Senior Management Roundtable, from a single...
Growing Complexity of Clinical Trials Increases Burden on Investigators and Volunteers, According to Tufts Center for the Study of Drug Development
15 janv. 2008 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - January 15, 2008) - More complex clinical trial protocols are
demanding more of investigative site personnel and study volunteers,
leading to longer clinical trials and...
Notable Gender, Racial Disparities Exist Among U.S. Clinical Investigators, According to the Tufts Center for the Study of Drug Development
13 nov. 2007 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - November 13, 2007) - Although the overwhelming majority of physicians
in the United States have high interest in participating in clinical
research studies, the actual...
Despite More Cancer Drugs in R&D, Overall U.S. Approval Rate Is Eight Percent, According to the Tufts Center for the Study of Drug Development
05 sept. 2007 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - September 5, 2007) - Although the number of new cancer drugs entering
clinical development more than doubled between the early 1990s and
mid-2000s, only eight percent of...